VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2011

Jul 7, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2011-07-06

Reporting Person: BOGER KENNETH S (SVP & General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-07-06	Common Stock	M	7333	$18.75	Acquired	120332	Direct
2011-07-06	Common Stock	S	7213	$50.29	Disposed	113119	Direct
2011-07-06	Common Stock	S	120	$51.73	Disposed	112999	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-07-06	Stock Option	$18.75	M	7333	Disposed	2011-09-23	Common Stock (7333)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5021	Indirect
Common Stock	174167	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $50.29 (range $50.00 to $50.73).

F3: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $51.73 (range $51.18 to $51.84).

F5: Kenneth S. Boger is the trustee for trusts established for the benefit of the three adult children of Joshua S. Boger (a director of the issuer).

F6: Fully vested.